Pfizer beats by $0.02, beats on revs; guides FY15 EPS below consensus, revs in-line
Reports Q1 (Mar) earnings of $0.51 per share, $0.02 better than the Capital IQ Consensus Estimate of $0.49. Include a $0.03 negative impact associated with an upfront payment to OPKO Health, Inc. (OPKO); revenues fell 4.0% year/year to $10.9 bln vs the $10.73 bln consensus.
Co issues mixed guidance (Guidance solely updated to reflect impact of FX) for FY15, sees EPS of $1.95-2.05 (Prior $2.00-2.10) vs. $2.11 Capital IQ Consensus Estimate; sees FY15 revs of $44-46 bln (Prior $44.5-46.54 bln) vs. $45.98 bln Capital IQ Consensus Estimate.
Co issues mixed guidance (Guidance solely updated to reflect impact of FX) for FY15, sees EPS of $1.95-2.05 (Prior $2.00-2.10) vs. $2.11 Capital IQ Consensus Estimate; sees FY15 revs of $44-46 bln (Prior $44.5-46.54 bln) vs. $45.98 bln Capital IQ Consensus Estimate.